Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. (Q50598579)

16 March 2018

title

Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. (English)

1 reference

16 March 2018

chronic obstructive pulmonary disease

main subject

patient

0 references

1 reference

4

1 reference

16 March 2018

Ulrike Held

11

1 reference

16 March 2018

Judith García-Aymerich

2

object named as

Judith Garcia-Aymerich

1 reference

16 March 2018

Milo A Puhan

1

1 reference

16 March 2018

Martin Frey

3

1 reference

16 March 2018

Josep M Antó

5

1 reference

16 March 2018

Alvar G Agustí

6

1 reference

16 March 2018

Federico P Gómez

7

1 reference

16 March 2018

Roberto Rodríguez-Roisín

8

1 reference

16 March 2018

Karel G M Moons

9

1 reference

16 March 2018

Alphons G Kessels

10

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 August 2009

1 reference

16 March 2018

published in

The Lancet

1 reference

16 March 2018

volume

374

1 reference

16 March 2018

issue

9691

1 reference

16 March 2018

page(s)

704-711

1 reference

16 March 2018

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

From COPD to chronic systemic inflammatory syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Global burden of COPD: risk factors, prevalence, and future trends

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

The modified BODE index: validation with mortality in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

The BODE index after lung volume reduction surgery correlates with survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Longitudinal change in the BODE index predicts mortality in severe emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Prognosis and prognostic research: what, why, and how?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

What do we mean by validating a prognostic model?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

External validation is necessary in prediction research: a clinical example

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Prognosis and prognostic research: validating a prognostic model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Toward a consensus definition for COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Characteristics of patients admitted for the first time for COPD exacerbation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

1 reference

7 January 2021

Review: a gentle introduction to imputation of missing values

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Development and Validation of an All-Cause Mortality Risk Score in Type 2 Diabetes The Hong Kong Diabetes Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Updating methods improved the performance of a clinical prediction model in new patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Validation and updating of predictive logistic regression models: a study on sample size and shrinkage.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Validation, calibration, revision and combination of prognostic survival models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Selection of important variables and determination of functional form for continuous predictors in multivariable model building

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Using regression models for prediction: shrinkage and regression to the mean

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Prognosis and prognostic research: Developing a prognostic model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Presentation of multivariate data for clinical use: The Framingham Study risk score functions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Interpretation of treatment changes in 6-minute walk distance in patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

The 6-min walk distance: change over time and value as a predictor of survival in severe COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Internal and external validation of predictive models: a simulation study of bias and precision in small samples

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Prediction of first coronary events with the Framingham score: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

C-reactive protein levels and survival in patients with moderate to very severe COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

COPD: more than respiratory.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

Prognosis and prognostic research: application and impact of prognostic models in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961301-5

7 January 2021

10.1016/S0140-6736(09)61301-5

Identifiers

DOI

1 reference

16 March 2018

PubMed ID

19716962

1 reference

16 March 2018